The survival of HER2 positive screen detected breast cancers in the abscence of chemotherapy and herceptin.

被引：0
|
作者：
Johnson, R. L. [1 ]
Prasad, R. [1 ]
Knox, W. F. [1 ]
Byrne, G. [1 ]
Morris, J. [1 ]
Cramer, A. [1 ]
Wilson, A. [1 ]
Bundred, N. J. [1 ]
机构：
[1] Univ S Manchester Hosp, Manchester M20 8LR, Lancs, England
来源：
BREAST CANCER RESEARCH AND TREATMENT | 2006年 / 100卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：S110 / S111
页数：2
相关论文
共 50 条
  • [31] Different Mechanisms for Acquired Resistance to Trastuzumab and Lapatinib in HER2 Positive Breast Cancers: Role of ER and HER2 Reactivation
    Wang, Y-C
    Hennessy, B.
    Ward, McAnnich R.
    Rimawi, M.
    Huang, C.
    Mills, G. B.
    Osborne, C. K.
    Schiff, R.
    CANCER RESEARCH, 2009, 69 (24) : 526S - 526S
  • [32] HER2 targeted therapy in breast cancer...beyond Herceptin
    Pal, Sumanta Kumar
    Pegram, Mark
    REVIEWS IN ENDOCRINE & METABOLIC DISORDERS, 2007, 8 (03) : 269 - 277
  • [33] HER2 targeted therapy in breast cancer...beyond Herceptin
    Sumanta Kumar Pal
    Mark Pegram
    Reviews in Endocrine and Metabolic Disorders, 2007, 8 : 269 - 277
  • [34] Synthetic lethality between HER2 and transaldolase in intrinsically resistant HER2-positive breast cancers
    Yi Ding
    Chang Gong
    De Huang
    Rui Chen
    Pinpin Sui
    Kevin H. Lin
    Gehao Liang
    Lifeng Yuan
    Handan Xiang
    Junying Chen
    Tao Yin
    Peter B. Alexander
    Qian-Fei Wang
    Er-Wei Song
    Qi-Jing Li
    Kris C. Wood
    Xiao-Fan Wang
    Nature Communications, 9
  • [35] Sparing chemotherapy with dual HER2 blockade in combination with endocrine therapy for advanced HER2 positive breast cancer
    Werutsky, Gustavo
    Reinert, Tomas
    Fay, Andre Poisl
    TRANSLATIONAL CANCER RESEARCH, 2018, 7 : S573 - S576
  • [36] The HER2 Amplicon Includes Several Genes Required for the Growth and Survival of HER2 Positive Breast Cancer Cells
    Hongisto, V.
    Sahlberg, K. Kleivi
    Edgren, H.
    Makela, R.
    Due, E.
    Vollan, H. K. Moen
    Sahlberg, N.
    Borresen-Dale, A. L.
    Perala, M.
    Kallioniemi, O.
    EUROPEAN JOURNAL OF CANCER, 2012, 48 : S82 - S83
  • [37] Optimal omission of anthracycline in adjuvant chemotherapy of HER2 positive breast cancer
    Watanuki, R.
    Hayashida, T.
    Yuko, K.
    Kikuchi, M.
    Nakashoji, A.
    Yokoe, T.
    Toyota, T.
    Seki, T.
    Takahashi, M.
    Kitagawa, Y.
    CANCER RESEARCH, 2019, 79 (04)
  • [38] Prediction of response to neoadjuvant chemotherapy in HER2 positive breast cancer by MammaTyper®
    Scatena, C.
    Belcastro, E.
    Scarpitta, R.
    Naccarato, A. G.
    EUROPEAN JOURNAL OF CANCER, 2024, 200 : 30 - 30
  • [39] The HER2 amplicon includes several genes required for the growth and survival of HER2 positive breast cancer cells
    Sahlberg, Kristine Kleivi
    Hongisto, Vesa
    Edgren, Henrik
    Makela, Rami
    Hellstrom, Kirsi
    Due, Eldri U.
    Vollan, Hans Kristian Moen
    Sahlberg, Niko
    Wolf, Maija
    Borresen-Dale, Anne-Lise
    Perala, Merja
    Kallioniemi, Olli
    MOLECULAR ONCOLOGY, 2013, 7 (03) : 392 - 401
  • [40] Synthetic lethality between HER2 and transaldolase in intrinsically resistant HER2-positive breast cancers
    Ding, Yi
    Gong, Chang
    Huang, De
    Chen, Rui
    Sui, Pinpin
    Lin, Kevin H.
    Liang, Gehao
    Yuan, Lifeng
    Xiang, Handan
    Chen, Junying
    Yin, Tao
    Alexander, Peter B.
    Wang, Qian-Fei
    Song, Er-Wei
    Li, Qi-Jing
    Wood, Kris C.
    Wang, Xiao-Fan
    NATURE COMMUNICATIONS, 2018, 9
12345